Theme research
Public Asthi digests where this theme appears in the market narrative.
daily digest
Chip weakness plus cloud capex headlines are making second‑order AI suppliers the cleaner way to track compute demand.
daily digest
Novo Nordisk sues Eli Lilly over GLP‑1 advertising; legal and reimbursement channels now sit alongside trials as near‑term confirmers for healthcare winners.
daily digest
Healthcare trial/regulatory cadence and defense backlog convertibility are the sharpest stock-level differentiators; consumer resilience helps demand‑sensitive names in the near term.
daily digest
A Medicare coverage shift for obesity drugs makes clinical and reimbursement calendars the immediate market lever for healthcare names.
daily digest
Power‑equipment order books and biotech trial timing are the clearest near‑term earnings signals — but the rate backdrop will determine how far single‑name strength can extend.
daily digest
Housing stays rate‑ and credit‑sensitive — watch 30‑year mortgage moves, inventory, and builder incentives for the next leg.
daily digest
Clinical trial data, M&A quietly reshaping mid‑cap pipelines, and strategist positioning make healthcare a catalyst‑driven sector this week.
daily digest
Catalyst-driven healthcare leadership persists, but fast-moving policy and China‑supply signals are changing which names face structural tailwinds or risks.
weekly digest
Markets are parsing cleaner bank fundamentals and discrete healthcare readouts while rates keep deciding who can run.
Asthi Research is general market commentary, not personalized investment advice. Public digests cite source coverage and become more useful when signed-in investors map themes back to their own holdings.